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Abstract
Background and Aims—CALGB 80303 was a randomized, phase III study in advanced
pancreatic cancer patients treated with gemcitabine plus either bevacizumab or placebo. We
prospectively collected germline DNA and conducted a genome-wide association study (GWAS)
using overall survival (OS) as the endpoint.
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Pancreatic cancer has a very poor prognosis and the lowest survival by stage of any solid tumor. Gemcitabine is the cornerstone of
chemotherapy in this disease but has a very modest impact. Novel molecular biomarkers are urgently needed. One approach is to
identify novel candidate genes putatively involved in the biology of pancreatic cancer. Through a genome-wide genotyping approach
in advanced pancreatic cancer patients treated with chemotherapy, this study identified novel variants in the IL17F gene as associated
with survival in advanced pancreatic cancer patients, through a mechanism putatively related to the anti-angiogenetic effects of
interleukin-17F. As patients with the variant allele have worse survival, this variant in IL17F could be validated as germline
prognosticator of survival of patients with advanced pancreatic cancer. Identification of prognostic markers in advanced pancreatic
cancer might improve the management of this disease. According to the results of the GWAS, new biological pathways could be
investigated to design novel strategies for therapeutic intervention.
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Methods—DNA from 351 patients was genotyped for >550,000 single nucleotide
polymorphisms (SNPs). Associations between OS and SNPs were investigated using the log-linear
two-way multiplicative Cox proportional-hazards model. The subset of 294 genetically European
patients was used for the primary analysis.
Results—A nonsynonymous SNP in IL17F (rs763780, H161R) and an intronic SNP in strong
linkage disequilibrium (rs7771466) were associated with OS using genome-wide criteria (p≤10−7).
Median OS was significantly shorter (p 2.61×10−8) for the rs763780 heterozygotes (3.1 months,
95% CI 2.3–4.3) as compared to the patients without this variant (6.8 months, 5.8–7.3). After
adjustment by stratification factors, the p value for the association was 9.51×10−7.
Conclusions—The variant 161R form of interleukin-17F is a natural antagonist of the anti-
angiogenic effects of wild-type 161H interleukin-17F, and angiogenesis may play an important
role in the metastatic spread of pancreatic cancer. In this preliminary study, we hypothesize that
the angiogenesis potential of pancreatic cancers in patients with variant interleukin-17F is higher
than that of tumors in patients with wild-type interleukin-17F, conferring worse prognosis. This
exploratory GWAS may provide the foundation for testing the biology and clinical effects of
novel genes and their heritable variants through mechanistic and confirmatory studies in
pancreatic cancer.
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INTRODUCTION
Pancreatic cancer has a very poor prognosis and the lowest survival by stage of any solid
tumor[1]. Gemcitabine is the cornerstone of chemotherapy in this disease but has a very
modest impact[2], and although numerous clinical trials have been conducted, only the
combination of gemcitabine and erlotinib achieved a modest increase in median OS over
gemcitabine alone[3]. Novel agents and/or novel molecular biomarkers are urgently needed.
One approach is to identify novel candidate genes putatively involved in the biology of
pancreatic cancer.
It is likely that germline variants will be able to predict the outcome of patients with cancer
and there is epidemiologic evidence that prognosis has an inherited component[4]. To test
this, we conducted a genome-wide association study (GWAS) in Cancer and Leukemia
Group B (CALGB) study 80303, a randomized, double-blind, phase III study in 602
advanced pancreatic cancer patients treated with gemcitabine plus either bevacizumab or
placebo. There was no superiority in OS of the gemcitabine-bevacizumab arm compared to
the gemcitabine-placebo arm[5].
As part of the study, we prospectively collected germline DNA for pharmacogenetic studies,
originally focusing on the association of candidate genes with treatment outcome. We
subsequently amended the study to conduct a genome-wide association study (GWAS) in
order to identify novel associations. In GWAS, germline DNA of patients can be scanned
using high-density single-nucleotide polymorphism (SNP) chips that assess hundreds of
thousands of SNP markers[6]. This approach is unbiased and does not rely on a priori
knowledge about the role of candidate markers for the outcome of interest. The goal of this
study was to identify novel genes associated with OS in pancreatic cancer.
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Clinical trial and patients
CALGB 80303 was a double-blind, placebo-controlled randomized (1:1) phase III multi-
institution study of bevacizumab, in combination with gemcitabine. Eligible patients had
histologically or cytologically confirmed adenocarcinoma of the pancreas not amenable to
potentially curative surgery, as previously described[7]. Patients were required to have an
ECOG performance status of 0–2 and adequate bone marrow, renal, and hepatic function.
Gemcitabine 1000 mg/m2 was given intravenously over 30 min on days 1, 8, and 15 of a 28-
day cycle. Bevacizumab, 10 mg/kg, or placebo was administered intravenously after
gemcitabine on days 1 and 15 of each 28-day cycle. Treatment was discontinued for
progressive disease, unacceptable adverse events, or patient withdrawal of consent.
Patients were stratified according to extent of disease (locally advanced vs. metastatic),
ECOG performance status (0–1, vs. 2) and prior radiotherapy (yes/no). Patients received a
minimum of two cycles of treatment unless unacceptable toxicity or early progression of
disease occurred. Patients were evaluated for response according to the Response Evaluation
Criteria in Solid Tumors[8] every 2 cycles. Confirmatory scans were obtained at least 4
weeks following initial documentation of objective complete or partial response. OS, with
date of randomization as its reference point, was the primary study endpoint.
The companion pharmacogenetic protocol (CALGB 60401) was approved by the
Institutional Review Boards of the University of Chicago and the Riken Institute. Only
patients who consented to CALGB 60401 were included in this study. The patient and tumor
characteristics of the subgroup of patients genotyped in this study are comparable to those of
patients in the main clinical trial (Table 1).
DNA samples and genotyping platforms
Of the 602 randomized patients on the main clinical study[5], blood samples were collected
from 365 patients who consented to the pharmacogenetic analysis, and were shipped to the
CALGB Pathology Coordinating Office (PCO) at Ohio State University. DNA was
extracted from a single 5–10 ml peripheral whole blood sample collected using EDTA
vacutainer tubes (purple tops) prior to beginning the study treatment using a commercially
available kit from Qiagen (Germantown, MD). The concentration and quality of DNA were
measured by ultraviolet spectrophotometry (Nanodrop, Wilmington, DE). DNA of sufficient
yield and quality (i.e. at least 2.5 µg and a minimum concentration of 50 ng/ml) was
obtained on 352 of the blood specimens (96%). DNA samples were randomly placed on a
96-deep well plate, each well containing one sample at a concentration of 50 ng/µl and
volume of 50 µl (by dilution with dH2O if needed).
The Illumina HumanHap550v3 Genotyping BeadChip was used to genotype >550,000 SNPs
in these samples. In addition, >7,000 SNPs in 267 candidate (i.e., hypothesized a priori to be
drug-related) genes were also genotyped in the same chip[9]. Genotyping was conducted at
the Center for Genomic Medicine, Riken Institute (Yokohama, Japan).
Quality control of the genotyping results and the phenotypic data (Figure 1)
Cases excluded from analysis were closely related patients. We assessed the relatedness
among patients by IBS, and the only individual removed from the IBS was one set of
duplicates (n=1) (as shown in Figure 1). Patients who were not treated or went off study
before completing 2 cycles of therapy were also excluded (n=13). The remaining 338
patients formed the basis for the association analyses. Among the 561,466 SNPs typed on
the platform, 44,108 SNPs were excluded due to call rates less than 95%. Among the
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remaining 517,538 SNPs, 21,894 SNPs with minor relative allelic frequencies (MAF) less
than 0.01 were removed. Finally, among the 495,464 remaining SNPs, 88 SNPs with strong
evidence for departure from Hardy-Weinberg equilibrium (HWE, p<10−8) were removed.
Among the 495,376 SNPs passing the filter, 484,523 were autosomal. Among these,
330,690 SNPs had a minor genotypic counts (MGC) >9 and were used in the association
analyses.
Patient registration, data collection, and data analysis were performed by the CALGB
Statistical Center. Data quality was ensured by careful review of data by CALGB Statistical
Center staff and the study chairperson.
Population structure analysis
Self-reported ethnicity information was available for each patient. However, this was
confirmed by estimating the genetic ancestral origin of patients using the principal
components analysis software implemented in Eigenstrat[10]. This was done by combining
our case data with the European, Asian, and African population SNP data from HapMap.
Genetically-European patients enrolled in CALGB 80303 were then selected by choosing
only those individuals that closely clustered with the European HapMap samples when using
all SNPs in the HumanHap550K BeadChip. This resulted in 294 patients of genetically-
estimated European ancestry, and in 26 patients of genetically-estimated African ancestry
(Supplemental Material, Figure 1). Also as shown in this figure, the CALGB 80303 samples
lined up as expected against the reference HapMap samples. A strong concordance between
genetically-estimated ancestry and self-reported race was observed.
Functional studies
The putative functional effects of the 20 most significant SNPs associated with OS were
examined using FastSNP (http://fastsnp.ibms.sinica.edu.tw/), a web-based bioinformatic
application[11]. Fast SNP can identify genetic regulatory regions, non-synonymous and
nonsense amino acid changes and determines the effects of SNPs on exon splicing enhancer
and silencer motifs, and transcription factor binding sites. For the same purpose, we also
have used our genome-wide data of gemcitabine cytotoxicity in lymphoblastoid cell
lines[12].
Statistical analysis of the associations
Our primary analysis determined the association between SNPs and OS in both arms
combined, in patients of European ancestry only. For the SNP by OS association analyses,
the Cox score (log-rank) test was used, and the analyses were powered against the additive
genetic model. The robustness of the genetic associations in the unadjusted analysis (i.e., our
primary analysis described above) was tested by including covariates in the model, testing
within the framework of a multivariable additive log-linear Cox proportional-hazards
model[13]. These covariates were: randomization stratification factors (performance status,
prior radiotherapy, and extent of disease), treatment arm, and genetic ancestry (based on the
three principal components). In the genome-wide feature selection process for the
genetically European population, only SNPs with MGC>9 were considered. The most
significant SNP, IL17F rs763780 for OS in patients of European ancestry was also tested in
the patients of African ancestry, in an unadjusted analysis. The coxph function from the
R[13] extension package survival[14] was used. The p values were not adjusted for multiple
comparisons. For a Q-Q plot, see Supplemental Material (Figure 2). We have used 1×10−7
(0.05/500,000) as the p value cut-off for genome-wide significance.
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The OS (median, 95% CI) in the genotyped patients of European ancestry was 6.3 months
(5.1–8.0) in the placebo arm and 5.9 months (4.9–7.1) in the bevacizumab arm, comparable
to the median OS observed in the overall clinical study[5]. The number of available SNPs
for association with OS was 484,523. Here we present the results of the primary analysis of
the SNP vs. OS association in patients of European ancestry (n=294), in both arms
combined (Figure 2).
Of the 20 SNPs that showed the most significant association with OS, nine were in
annotated genes, one was near a gene, and ten were in intergenic regions (Table 2). All
SNPs in genes were intronic, with the exception of the coding SNP rs763780 in IL17F. The
SNP with the highest statistical significance was rs763780 in IL17F (p 2.61×10−8), with a
MAF of 0.04 (Figure 2). Patients who were rs763780 heterozygous had reduced median OS
of 3.1 months (2.3–4.3) compared to patients without the variant (no patients were
homozygous for the variant), who had a median OS of 6.8 months (5.8–7.3, Figure 3A).
This SNP was also in strong linkage disequilibrium (r2 0.955) with another IL17F SNP
(rs7771466) having the second highest statistical significance (p 1.66×10−7) and a similar
effect on OS [3.1 months (2.4–4.3) vs. 6.6 months (5.8–7.2)]. A similar trend was observed
in the subset of patients of African ancestry (Supplemental Material, Figure 3). The
associations between the SNPs in IL17F and OS, after adjusting for the stratification factors,
treatment arm, and genetic ancestry within Europeans, do not meet the criterion for genome-
wide statistical significance (1×10−7) (Supplemental Material, Table 1).
In silico analysis of the putative function of the intronic IL17F rs7771466 variant (in very
strong LD with the non-synonymous rs763780) indicates that a) rs7771466 introduces an
additional CDX1 transcription factor binding site to one present in the wild-type sequence,
and b) rs763780 abolishes an exonic splicing silencer and introduces two exonic splicing
enhancers (Supplementary Material, Table 2).
DISCUSSION
We interrogated >550,000 heritable variants in patients with advanced pancreatic cancer
treated with chemotherapy in CALGB 80303. To our knowledge, this is the first GWAS in a
cancer patient population in the context of a randomized, placebo-controlled, clinical trial.
This preliminary study generates hypotheses on the role of the IL17F gene in the biology of
advanced pancreatic cancer. If replicated, the IL17F SNPs might have prognostic
significance.
IL17F encodes interleukin-17F, a cytokine with the ability to induce stromal cells to secrete
pro-inflammatory cytokines. The most significant SNP in this study is rs763780 in IL17F, a
base substitution that alters the histidine to arginine at amino acid 161 (H161R). In vitro
functional experiments demonstrated that, in contrast to the wild-type 161H interleukin-17F,
the 161R variant form lacks the ability to activate the mitogen-activated protein kinase
pathway, thereby restricting cytokine and chemokine production[15]. Wild-type 161H
interleukin-17F has also demonstrated a strong anti-angiogenesis effect by markedly
inhibiting the angiogenesis of human endothelial cells and inducing them to produce
interleukin-2, TGF-beta, and monocyte chemoattractant protein-1[16]. A recent study has
also shown the anti-angiogenetic and anti-tumor properties of wild-type interleukin-17F in
vivo[17]. With respect to these activities, the variant 161R form of interleukin-17F is a
natural antagonist of the anti-angiogenic and pro-inflammatory effects of wild-type 161H
interleukin-17F. For example, the 161R variant has been associated with protective effects
in Asian patients with inflammatory and autoimmune conditions[18, 19]. The resulting pro-
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angiogenic effects of the variant 161R of interleukin-17F could be further magnified by the
concomitant increased expression driven by the noncoding rs7771466 IL17F variant. This
variant is almost in complete linkage disequilibrium with the nonsynonymous rs763780, and
its minor allele seems to increase interleukin-17F expression through splicing enhancement
and introduction of an additional CDX1 transcription factor binding site. The putative
synergistic effect of these IL17F variants should be verified in experimental models of SNP
functionality and angiogenesis.
As angiogenesis has been thought to play an important role in the growth and metastatic
spread of pancreatic cancer[20], we hypothesize that the angiogenesis potential of tumors of
patients with the variant 161R interleukin-17F is higher than tumors with wild-type 161H
interleukin-17F, conferring worse prognosis. However, other mechanisms related to the pro-
inflammatory effects of interleukin-17F cannot be excluded.
The IL17F rs763780 is the most important candidate SNP discovered by this study, due to 1)
the genome-wide significance, 2) its already established molecular function, 3) the
mechanistic hypothesis explaining the association with reduced OS, and 4) the suggestion
that a trend could be detected in patients of African ancestry, despite the very small sample
size. This study proposes that rs763780 in IL17F might have a prognostic effect in advanced
pancreatic cancer patients, also because stratification by treatment arm does not seem to
negatively affect the association (Supplemental Material, Table 1). Because gemcitabine is
given in both arms, a true interaction between gemcitabine and IL17F SNPs cannot be
tested. Additionally, a review of the clinical characteristics of the patients heterozygous for
IL17F rs763780 did not show any obvious difference with respect to the characteristics of
the overall population accrued into this study (data not shown).
In addition to IL17F, this study proposes additional genes as putatively involved in
determining differences in survival among patients with advanced pancreatic cancer. Among
the SNPs listed in Table 2, rs11644322 in WWOX demonstrated a gene-dosage effect, with
median OS in the heterozygous patients (5.3 months, 4.3–6.9) that was intermediate between
the other two genotype groups (3.3 months, 2.9–5.7, for the variant homozygotes; 7.1
months, 6.0–8.4, for the wild-type homozygotes; p 1.31×10−5; Figure 3B). WWOX codes
for the WW domain-containing oxidoreductase, a tumor suppressor in several tumors,
including pancreatic cancer[21]. WWOX SNPs showed the strongest linkage for prostate
cancer susceptibility in a recent genome-wide scan[22]. In multiple myeloma, loss of
heterozygosity of 16q23, the location of WWOX, was associated with adverse survival and
reduced WWOX expression[23]. Germline variants from a recent study mapped WWOX as
one of the genes associated with clinical staging in lung cancer[24]. Contrary to the amino
acid changing SNP in IL17F, the molecular functions of the SNPs in WWOX are not known
at this time. Due to their association with reduced OS, the established tumor suppressor role
of WWOX, and their intronic location, we hypothesize that these SNPs might reduce the
expression of WWOX, diminishing its tumor suppressor properties, and leading to worse
prognosis.
A SNP (rs10883617) near BTRC was associated with reduced OS, as homozygote patients
had a reduced median OS (3.6 months, 2.7–6.8) compared to heterozygous patients (6.1
months, 4.9–7.3) and patients who were not carriers of this variant (6.9 months, 5.9–8.2; p
3.94×10−5, Figure 3C). BTRC (beta-transducin repeat containing) encodes a protein
involved in the ubiquitination processes that demonstrated an oncogenic activity in several
cancers including pancreatic cancer[25–27]. In most tumors, overexpression of BTRC
results in the degradation of IKappaB, an inhibitor of the NFkappaB transcription factor, and
thus the activation of NFkappaB and the uncontrolled cell proliferation in these tumors. The
use of our functional results in lymphoblastoid cell lines treated with gemcitabine indicated
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that BTRC rs10883617 is associated with increased IC50 and, hence, resistance to
gemcitabine (r 0.21, p 0.008). As inhibiting and silencing NFkappaB have been shown to
increase the sensitivity of pancreatic cancer cells to gemcitabine[28, 29], we hypothesize
that BTRC rs10883617 might have a predictive value in pancreatic cancer patients treated
with gemcitabine, via a NFkappaB-mediated effect.
This study is limited by the large number of multiple comparisons typical of GWAS,
increasing the chance of false positive associations. This limitation could be overcome by
independent replication of the findings. Replication studies in cancer treatment outcome
have intrinsic difficulties, as there may not be an existing trial (to be used for replication)
with the same eligibility criteria and drug treatment of the trial used for discovery. In a
relatively uncommon disease like pancreatic cancer, the access to a sufficiently powered
replication set is particularly challenging. Ideally, validation of our top hits should be
conducted in patients treated with gemcitabine and randomized to an experimental
treatment, in order to ensure that the populations are comparable. A few published trials[30,
31] where patient DNA has been already collected may be considered for replication, due to
similarity of treatment and/or disease, and randomized treatment. Additionally, the MAF of
the variants in IL17F is low in Caucasians (0.05 from HapMap), potentially limiting the
ability to replicate this association in this population. However, the MAF of the variants in
IL17F is higher in Asians (0.13).
The results of this study are preliminary because of the limited sample size and the low
MAF of the IL17F SNP. Due to the refractoriness to treatment of advanced pancreatic
cancer and the lack of established markers of survival, the dissemination of these findings to
the scientific community could facilitate their replication by others, even as we continue to
conduct replication and validation studies. The association of IL17F variants with efficacy
could be also tested in tumors other than pancreatic cancer. To support this, our data are now
available in dbGaP, in accordance with NIH policy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Flow chart of the quality control process in 352 initial patients genotyped with 561,466
SNPs
IBS, identity by state; MAF, minor relative allelic frequency; MGC, minor genotypic
counts.
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Figure 2. Manhattan plot of SNPs associated with OS in patients of European ancestry with both
arms combined
The observed marginal P-values (minus log base 10 scale) are plotted across the
chromosomes.
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Figure 3. Kaplan-Meier estimate of OS stratified by (A) rs763780 IL17F, (B) rs11644322 WWOX,
and (C) rs10883617 BTRC genotypes in patients of European ancestry with both arms combined
For rs763780, A/A, non carriers of rs763780; A/G, heterozygotes. For rs11644322, G/G,
non carriers of rs11644322; G/A, heterozygotes; A/A, homozygotes. For rs10883617, A/A,
non carriers of rs10883617; A/G, heterozygotes; G/G, homozygotes. The base change is
according to the Illumina TOP stranding method for determining strand and allele[33].
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